<DOC>
	<DOCNO>NCT01681680</DOCNO>
	<brief_summary>The current study part large multi-investigator grant look pharmacogenetics number membrane transporter . The investigator study individual particular genotype human organic cation transporter , ( hOCT2 ) , multidrug toxin extrusion transporter , MATE1 , MATE2-K test hypothesis genetic variation hOCT2 , hMATEE1 hMATE2-K associate variation pharmacokinetics and/or pharmacodynamics antidiabetic agent , metformin .</brief_summary>
	<brief_title>Effect Genetic Variation Transporter OCT2 , MATE1 MATE2-K PKPD Metformin</brief_title>
	<detailed_description>In propose study , genotype phenotype strategy employ study role transporter , OCT2 , MATE1 , MATE2-K relate variant response disposition know substrate , metformin . Recently , one polymorphic variant MATE1 ( PMT4302 , g.-66T &gt; C ) show decreased promoter activity 40-45 % ( p &lt; 0.01 ) , one MATE2-K variant ( PMT5597 , g.-130G &gt; A ) show increased promoter activity 30 % ( p &lt; 0.05 ) , compare reference . Both common promoter variant gene ( frequency PMT4302 : 32.1 % 23.1 % Caucasian Asian ; PMT5597 : 26.2 % 48.5 % Caucasian Asian ) ( unpublished data , Giacomini group ) . Specifically , investigator measure renal clearance metformin , plasma glucose insulin level , healthy Caucasian Asian subject carry either reference variant allele order evaluate effect variant metformin disposition response .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects selfidentify racial background , identify , parent four grandparent Caucasian Chinese . Subject status healthy volunteer SOPHIE cohort Subjects 18 year old Subjects healthy basis medical history , physical examination laboratory test healthy volunteer SOPHIE Subjects agree write informed consent participate study . Under 18 year old Pregnant lactate woman ( female subject urine pregnancy test Day 1 visit ) They report prior history allergic reaction metformin Has risk congestive heart failure require pharmacologic treatment ( medical history ) Has prior history renal* hepatic dysfunction ( renal hepatic function evaluate base screen blood test conduct prior study enrollment ) Anemic ( screen lab value , hemoglobin &lt; 10 g ) Taking medication could confound study result ( know substrates inhibitor OCT2 , MATE1 MATE2K cimetidine ) Subjects undergoing radiologic study involve intravascular administration iodinate contrast material , use product may result acute alteration renal function They consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>